Home Latest Articles
Latest Articles
  • Weiguo JI, Weiwei LI, Yan SHAN, Weiming LI, Haisong LU, Kaixun HAN
    World Clinical Drug. 2025, 46(3): 236-242.
    Objective

    To explore the effect of Guifu Dingchuan granules as an adjuvant treatment of cough and asthma in the middle and advanced non-small cell lung cancer(NSCLC) with kidney Qi deficiency syndrome.

    Methods

    A total of 100 patients with cough and asthma in the middle and advanced NSCLC with kidney Qi deficiency syndrome in our hospital from December 2022 to January 2024 were selected and divided into control group(western medicine) and study group(Guifu Dingchuan granules combined with western medicine) according to simple sequencing random method, with 50 cases in each group. The clinical effect of the two groups was observed. The traditional Chinese medicine syndrome score, forced expiratory volume in one second(FEV1), peak expiratory flow(PEF), forced vital capacity(FVC), serum micro RNA(miR)-200a, miR-375, Leicester cough questionnaire(LCQ), quality of life questionnaire-core 30(QLQ-C30)and incidence of adverse reactions were compared before and after treatment.

    Results

    The total effective rate of the study group was higher than that of the control group(92.00% vs. 76.00%, P<0.05). After treatment, LCQ and QLQ-C30 scores in the study group were lower than those in the control group(P<0.05). The levels of FEV1, PEF, FVC, serum miR-200a and miR-375 in the study group were higher than those in the control group(P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).

    Conclusion

    Guifu Dingchuan granules can effectively improve the curative effect, improve lung function and quality of life in the adjuvant treatment of cough and asthma in the middle and advanced NSCLC patients with kidney Qi deficiency syndrome, and up-regulate the levels of serum miR-200a and miR-375 with high safety.

  • Jiao LYU, Hongying ZHAO, Mei ZHU
    World Clinical Drug. 2025, 46(3): 243-248.
    Objective

    To observe the clinical effect of calcium polycarbophil in the treatment of opioid-induced constipation(OIC).

    Method

    A total of 204 OIC patients treated in our hospital from June 2022 to December 2023 were selected and divided into control group and study group according to a simple randomization method, with 102 cases in each group. They were respectively treated with glycerin enema for rectal administration and oral administration of calcium polycarbophil tablets for 2 weeks. The average number of completely spontaneous bowel movement(CSBM) per week, Bristol stool form scale(BSFS), bowel function index(BFI), numerical rating scale(NRS) for pain, patient assessment of constipation-quality of life(PAC-QOL) and serum inflammatory factor levels were compared between the two groups before and after treatment.

    Result

    After treatment, the proportion of patients with CSBM≥3 times per week or an increase of ≥1 time compared with the baseline in the study group was significantly higher than that in the control group(50.0% vs. 31.4%,P<0.05). The number of patients with BSFS types 3~4 in the study group was significantly higher than that in the control group(57.8% vs. 40.2%,P<0.05). After treatment, BFI and PAC-QOL scores, IL-6 and hs-CRP levels in both groups were lower than before treatment(P<0.05), and the study group was lower than the control group. There was no significant difference in NRS score between the two groups before and after treatment(P>0.05).

    Conclusion

    Calcium polycarbophil can effectively improve the symptoms of constipation and quality of life in OIC patients, and reduce the level of serum inflammatory factors, which is worthy of clinical promotion.

  • Le CHEN, Mingying ZHANG
    World Clinical Drug. 2025, 46(3): 249-253.
    Objective

    To investigate the effect of Yiqi Yangyin Huoxue Jiangzhuo decoction on the treatment of early and middle stage type 2 diabetes mellitus(T2DM) patients with kidney disease and its influence on renal function and urinary protein.

    Methods

    A total of 96 patients with early and middle stage T2DM renal disease in our hospital from January 2023 to September 2024 were selected as the study objects. The subjects were divided into control group and study group by simple random method, with 48 cases in each group. Both groups were treated with conventional western medicine, and the study group was additionally treated with Yiqi Yangyin Huoxue Jiangzhuo decoction, both groups were treated continuously for 3 months. The clinical efficacy, TCM syndrome score, urinary protein, renal function, inflammatory factors and safety of the two groups were compared.

    Results

    After treatment, the clinical effect of the study group was higher than that of the control group(91.67% vs. 77.08%, P<0.05). The TCM syndrome score of the study group was lower than that of the control group(P<0.05). The levels of urinary microalbumin, 24 hours urine total protein, creatinine, urea nitrogen, blood uric acid, C-reactive protein, tumor necrosis factor-α and interleukin-6 in the study group were lower than those in the control group(P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).

    Conclusion

    Yiqi Yangyin Huoxue Jiangzhuo decoction is effective in adjuvant treatment of early and middle stage T2DM patients with kidney disease, which can effectively improve clinical symptoms and renal function, reduce urinary protein and the expression inflammatory factors, and do not increase the occurrence of adverse reactions.

  • Dandan DONG, Li QIU, Yi HU, Jianzhong LIU
    World Clinical Drug. 2025, 46(3): 254-259.
    Objective

    To investigate the efficacy of lenvatinib in treating liver cancer patients after radiofrequency ablation(RFA) and its effects on serum alpha-fetoprotein variant(AFP)-L3, AFP, abnormal prothrombin(DCP) levels and immune function.

    Methods

    A total of 209 patients with liver cancer admitted to our hospital from August 2021 to August 2024 were selected and divided into control group(n=105) and experimental group(n=104). After RFA treatment, the control group was treated with FOLFOX regimen, and the experimental group was treated with lenvatinib. Clinical efficacy, serum AFP-L3, AFP and DCP levels, immune function and the changes of aspartate aminotransferase(AST), alanine aminotransferase(ALT), total bilirubin(TBil) levels and complications were observed in the two groups.

    Results

    After treatment, the clinical effect of experimental group was higher than that of control group(85.71% vs. 69.23%)(P<0.05). Serum levels of AFP-L3, AFP and DCP in both groups were decreased compared with those before treatment, and the experimental group was lower than the control group (P<0.05). The levels of cluster of differentiation(CD)3+, CD4+ and CD4+/CD8+ in both groups were increased compared with before treatment, and the experimental group was higher than the control group (P<0.05). The levels of CD8+, AST, ALT and TBil in both groups were all decreased than before treatment, and the experimental group was lower than the control group(P<0.05). There was no significant difference in the total incidence of complications between the two groups(P>0.05).

    Conclusion

    Lenvatinib combined with RFA can improve the level of AFP-L3, AFP, DCP and immune function, and improve the control effect of tumor in patients with liver cancer.

  • Chunling QIAO, Yuqi ZHANG, Yanyan LI, Ning ZHANG
    World Clinical Drug. 2025, 46(3): 260-265.
    Objective

    To analyze the effects of transumbilical laparoendoscopic single site surgery(LESS) combined with dexmedetomidine in the treatment of congenital intestinal atresia(CIA) on intestinal function, serum neuron-specific enolase(NSE) level, growth hormone(GH), insulin-like growth factor binding protein(IGFBP)-3 and markers of intestinal barrier function.

    Methods

    A total of 206 newborns with CIA admitted to our hospital from June 2022 to June 2024 were selected as the study objects and randomly divided into observation group and control group, with 103 cases in each group. The control group received LESS, and the observation group was treated with dexmedetomidine on the basis of control group. The time of indwelling gastric tube, first exhaust time, the incidence of complications and intestinal function recovery were compared between the two groups after surgery.

    Results

    The incidence of intestinal obstruction, anastomotic impotence, diarrhea and other complications in the observation group was lower than that in the control group(P<0.05), and the time of indwelling gastric tube and first exhaust time were shorter than those in the control group(P<0.05). The levels of total protein, albumin and hemoglobin in the observation group were significantly better than those in the control group(P<0.05). The refeeding time and the whole feeding time of the observation group were shorter than those of the control group(P<0.05). The improvement of serum NSE in the observation group was better than that in the control group(P<0.05), and the levels of GH and IGFBP-3 were higher than those in the control group(P<0.05). The levels of intestinal barrier function markers in the observation group were higher than those in the control group, and the intestinal permeability was significantly improved compared with the control group(P<0.05).

    Conclusion

    LESS combined with dexmedetomidine can reduce the incidence of complications after CIA, shorten the postoperative recovery time, improve enteral nutrition, regulate serum NSE level, promote the level of GH and IGFBP-3, and improve intestinal barrier function, which has certain clinical value.

  • Tiansong XU, Huanghao FAN, Gangcheng XIE, Yun WANG
    World Clinical Drug. 2025, 46(3): 266-270.
    Objective

    To investigate the effect of mulberry twig alkaloids tablets combined with metformin on serum insulin-like growth factor(IGF)-1, fibroblast growth factor(FGF)21, adipocytokin(Apelin)-13 and islet function in patients with type 2 diabetes mellitus(T2DM).

    Methods

    A total of 137 T2DM patients treated in our hospital from June 2022 to May 2023 were selected and randomly divided into combination group(n=69, metformin+mulberry twig alkaloids tablets) and control group(n=68, metformin) by random number table method. Both groups were treated continuously for 4 weeks. The clinical efficacy, IGF-1, FGF21, Apelin-13, islet function, glucose metabolism and adverse reactions were compared between the two groups after treatment.

    Results

    After treatment, the total effective rate of the two groups was significantly different(92.75% vs. 66.18%, P<0.05). Serum IGF-1, FGF21, insulin resistance index, fasting blood glucose, 2-hour postprandial blood glucose and glycosylated hemoglobin levels in both groups were significantly lower than before treatment, and the combination group was lower than the control group(P<0.05). The levels of Apelin-13, islet β cell function index and insulin action index in both groups were significantly increased than before treatment, and the combination group was higher than the control group(P<0.05). There was no significant difference in drug safety between the two groups(P>0.05).

    Conclusion

    The application of mulberry twig alkaloids tablets combined with metformin in T2DM can improve serum IGF-1, FGF21, Apelin-13 and islet function, effectively lower blood glucose, with good safety.

  • Le YING, Yu TAO, Hongbo YANG, Nan SONG, Yuzhu YANG
    World Clinical Drug. 2025, 46(3): 271-276.
    Objective

    To investigate the effects of bevacizumab combined with chemotherapy regimen on neutrophil-to-lymphocyte ratio(NLR), platelet-to-lymphocyte ratio(PLR), utrophil-to-lymphocyte ratio(NWR), lymphocyte-to-white blood cell ratio(LWR) and lymphocyte subpopulations in patients with lung adenocarcinoma.

    Methods

    A total of 102 patients with lung adenocarcinoma who received treatment in Baozhang Hospital from March 2022 to March 2024 were randomly divided into study group and control group, with 51 cases in each group. Both groups were treated with programmed death receptor 1 inhibitor+pemetrexed+platinum, while the study group was additionally treated with bevacizumab. The therapeutic efficacy, blood routine, lymphocyte subsets, Karnofsky performance status(KPS) score and the occurrence of adverse reactions were compared between the two groups after treatment.

    Results

    After treatment, the total effective rate of the study group was higher than that of the control group(82.35% vs. 60.78%, P<0.05). The levels of NLR, PLR, NWR and LWR in both groups were decreased compared with those before treatment, and the study group was lower than the control group(P<0.05). The levels of natural killer cells and cluster of differentiation(CD)4+/CD8+in both groups were increased compared with those before treatment, and the study group was higher than the control group(P<0.05). The KPS score of the study group was higher than that of the control group[(89.91±6.62) points vs.(83.44±8.93) points, P<0.05]. There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).

    Conclusion

    Bevacizumab as an adjuvant therapy for lung adenocarcinoma can enhance the efficacy, improve the levels of NLR, PLR, NWR, LWR and lymphocyte subpopulations in patients, and does not increase the occurrence of adverse reactions.

  • Changqing MAO, Lianlian NIE, Yonghuan CAO, Weihua SHEN, Yong WANG, Yuyao JIN
    World Clinical Drug. 2025, 46(3): 277-283.
    Objective

    To investigate the status of medication compliance and its influencing factors in some patients with diabetes mellitus(DM) in Jinshan district of Shanghai, and to analyze the relationship between them, so as to explore the mediating effects of medication compliance in the progression of dietary habits and DM complications.

    Methods

    DM patients registered in 3 community health service centers in Langxia, Zhangyan and Zhujing, Jinshan district of Shanghai were randomly selected by cluster sampling, and the participants were investigated. The investigation included general information of patients, medication compliance and complications. Logistic regression model was used to analyze the influence of various variables on medication compliance, and SAS9.4 and R4.3.3 were used to complete statistical analysis.

    Results

    A total of 1 173 DM patients were investigated. The average score of medication compliance was (7.51±0.80), of which 750 patients(63.94%) had medication compliance, and 423 patients(36.06%) had poor medication compliance.Logistic regression analysis showed that the group with dietary preferences had worse medication compliance than that with balanced diets(odds ratio: 3.45, 95% confidence interval: 2.40 - 4.98), and the risk of DM cardiovascular disease and diabetic foot(DF) was higher(P<0.05). The results of mediating analysis showed that medication compliance played a partial mediating role in the relationship between dietary habits and DM cardiovascular diseases and DF, and the mediating effect ratio was 18.34% and 22.93%, respectively.

    Conclusion

    The overall medication compliance of DM patients in Jinshan district of Shanghai was good. Dietary habit is an important factor affecting the medication compliance of DM patients, and dietary preference is an important factor affecting DM cardiovascular disease and DF. Medication compliance plays a partial mediating role between dietary habits and the occurrence of DM cardiovascular disease and DF.

  • Zhiyuan LI, Tierong BIAN, Qian LIU, Tao MA, Qulian GUO, Hongyun XING
    World Clinical Drug. 2025, 46(3): 284-290.
    Objective

    To analyze the efficacy of low-dose venetoclax combined with azacitidine and voriconazole in elderly patients with acute myeloid leukemia(AML).

    Methods

    Clinical data of elderly AML patients hospitalized in the affiliated hospital of southwest medical university from June 2021 to June 2023 were collected. All patients completed 4 cycles of venetoclax combined with azacitidine. The efficacy and safety of different treatment schemes were compared.

    Results

    A total of 45 patients were enrolled, of which 12 patients were treated with standard dose of venetoclax+azacitidine, and 33 patients were treated with low-dose venetoclax+azacitidine+voriconazole. In the low-dose group, 24 patients(72.7%) were evaluated as complete remission(CR) or CR with incomplete count recovery(CRi) after treatment. A total of 19 patients(57.6%) achieved negative response on minimal residual lesion(MRD). In the standard-dose group, 10 patients(83.3%) were assessed for CRi and 3 patients(25.0%) achieved MRD-negative response. In addition, patients with SRSF2, BCOR, NPM1, or IDH1/2 gene mutations were observed to be more sensitive to treatment. The incidence of granulocytopenia, thrombocytopenia, elevated transaminase, electrolyte disturbance, anemia, hypoproteinemia and infection in low dose group was higher than that in standard dose group. Both the mean and median overall survival(OS)in the standard-dose group were significantly longer than those in the low-dose group.

    Conclusion

    In the treatment of elderly AML with low-dose venetoclax+azacitidine regimen, combined with voriconazole for antifungal therapy can increase the effective plasma concentration of venetoclax without increasing the CR/CRi rate. However, compared with the standard dose regimen, but treatment-related adverse events increased and OS was shortened.

  • Yang MA, Congying FAN, Shuowen WANG, Guorong FAN
    World Clinical Drug. 2025, 46(3): 291-294.
News